The amylin field is heating up ahead of Novo Nordisk’s much-anticipated CagriSema readout later this year.
The US Government Accountability Office published a new report detailing concerns with the staffing of the FDA’s ...
Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in ...
Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...
TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...
Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...
Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...
BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...
Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its ...
A lot of Amgen’s future rides on its experimental obesity medicine MariTide. At least in the minds of investors.
AstraZeneca CEO Pascal Soriot affirms commitment to China despite investigation involving China president Leon Wang and other employees. Wang, who reported directly to Soriot, and former AstraZeneca ...
Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several preclinical ...